Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Pasta

Showing results (151-160 of 162) with videos related to

Pageof 17
Sort By:
The Journal of Urology|March 11, 2005
The impact of obesity on health related quality of life before and after radical prostatectomy (data from CaPSURE)Jason W Anast, Natalia Sadetsky, David J Pasta, et al.
Urology|November 16, 2005
Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSUREWilliam W Bassett, Matthew R Cooperberg, Natalia Sadetsky, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 5, 2017
Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutationJeffrey S Wagener, Stefanie J Millar, Nicole Mayer-Hamblett, et al.
Cancer|October 14, 2006
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomyMatthew R Cooperberg, Stephen J Freedland, David J Pasta, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 10, 2025
Real-world association between ivacaftor initiation and lung function variability: A registry studyRhonda D Szczesniak, Eleni-Rosalina Andrinopoulou, Hancheng Li, et al.
Chest|February 18, 2019
Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment StrategiesRaymond L Benza, Mardi Gomberg-Maitland, C Greg Elliott, et al.
The Journal of Pediatrics|July 24, 2007
Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosisMichael W Konstan, Wayne J Morgan, Steven M Butler, et al.
Pulmonary Therapy|November 2, 2022
Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene MutationGregory S Sawicki, Michael W Konstan, Edward F McKone, et al.
The Lancet. Respiratory Medicine|December 25, 2016
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension studyMichael W Konstan, Edward F McKone, Richard B Moss, et al.
Annals of the American Thoracic Society|September 8, 2025
Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies After Rapid Adoption: A Dual-Approach StudyPedro Miranda Afonso, Grace C Zhou, Weiji Su, et al.
Pageof 17

Showing results (151-160 of 162) with videos related to

Sort By:
Pageof 17
The Journal of Urology|March 11, 2005
The impact of obesity on health related quality of life before and after radical prostatectomy (data from CaPSURE)Jason W Anast, Natalia Sadetsky, David J Pasta, et al.
Urology|November 16, 2005
Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSUREWilliam W Bassett, Matthew R Cooperberg, Natalia Sadetsky, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 5, 2017
Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutationJeffrey S Wagener, Stefanie J Millar, Nicole Mayer-Hamblett, et al.
Cancer|October 14, 2006
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomyMatthew R Cooperberg, Stephen J Freedland, David J Pasta, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 10, 2025
Real-world association between ivacaftor initiation and lung function variability: A registry studyRhonda D Szczesniak, Eleni-Rosalina Andrinopoulou, Hancheng Li, et al.
Chest|February 18, 2019
Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment StrategiesRaymond L Benza, Mardi Gomberg-Maitland, C Greg Elliott, et al.
The Journal of Pediatrics|July 24, 2007
Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosisMichael W Konstan, Wayne J Morgan, Steven M Butler, et al.
Pulmonary Therapy|November 2, 2022
Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene MutationGregory S Sawicki, Michael W Konstan, Edward F McKone, et al.
The Lancet. Respiratory Medicine|December 25, 2016
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension studyMichael W Konstan, Edward F McKone, Richard B Moss, et al.
Annals of the American Thoracic Society|September 8, 2025
Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies After Rapid Adoption: A Dual-Approach StudyPedro Miranda Afonso, Grace C Zhou, Weiji Su, et al.
Pageof 17